Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aleksey Prok

Interventional Pain Medicine Lima, OH Medical Doctor

NPI 1912942400 CMS profile 1158221

1003 Bellefontaine Ave Ste 100, Lima, OH 45804

Open in the dashboard

General payments

$3,191

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aleksey Prok of Lima, OH is reported in the CMS Open Payments database as having received $3,191 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $198 9
2024 General $315 15
2023 General $1,712 29
2022 General $417 27
2021 General $184 9
2020 General $123 7
2019 General $242 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aleksey Prok
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Aleksey Prok were reported at $198. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Aleksey Prok Interventional Pain Medicine median Middle half National median
2019 $242 $684 $216–$2,079 $163
2020 $123 $382 $122–$1,109 $114
2021 $184 $552 $167–$1,554 $132
2022 $417 $605 $187–$1,924 $149
2023 $1,712 $671 $195–$1,915 $160
2024 $315 $684 $206–$1,837 $164
2025 $198 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,850 36 payments
  2. Boston Scientific Corporation $284 10 payments
  3. Collegium Pharmaceutical, Inc. $213 20 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $148 9 payments
  5. SPR Therapeutics, Inc $140 5 payments
  6. Medtronic USA, Inc. $110 4 payments
  7. Nevro Corp. $68 4 payments
  8. TerSera Therapeutics LLC $61 4 payments
  9. Stryker Corporation $46 1 payment
  10. SI-BONE, Inc. $35 2 payments
  11. Other $236 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,417 103 payments
  2. Travel and Lodging $775 5 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMEDII $1,352 18 payments
  2. INTELLIS ADAPTIVESTIM $377 14 payments
  3. XTAMPZA $213 20 payments
  4. SPRINT PNS System $140 5 payments
  5. RELISTOR Gastroenterology $98 5 payments
  6. INJEX $79 1 payment
  7. SYNCHROMED $70 1 payment
  8. Senza Spinal Cord Stimulation System $68 4 payments
  9. PRIALT $61 4 payments
  10. RELISTOR Gastroenterology $50 4 payments
  11. Other $746 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,142

Median for Pain Management: 951

Drug cost

$34,234

Median for Pain Management: $26,034

Branded share of claims

45.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 238 $6,697
Xtampza Er Oxycodone Myristate Brand 13 $6,651
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 261 $5,873
Pregabalin Generic 49 $5,604
Gabapentin Generic 104 $2,121
Oxycodone Hcl Generic 85 $1,455
Tramadol Hcl Generic 141 $1,276
Fentanyl Generic 20 $1,230
Baclofen Generic 42 $881
Tizanidine Hcl Generic 45 $737

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$56,366

Medicare's payments for the services billed

Medicare patients

166

Average age 71

Services billed

697

92 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Diabetes 40%
Depression 32%
Chronic kidney disease 31%
COPD 30%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record